Duration of triple antithrombotic therapy and clinical outcomes after percutaneous coronary intervention in atrial fibrillation.

ABSTRACT:

Background

Triple antithrombotic therapy (TAT) with aspirin, a P2Y₁₂ inhibitor, and oral anticoagulation in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) raises concerns about increased bleeding. Regimens incorporating more potent P2Y₁₂ inhibitors over clopidogrel have not been investigated adequately.

Research design and methods

A retrospective observational study was performed on 387 patients with AF receiving TAT for 1 month (n = 236) or ≤1 week (n = 151) after PCI. Major and clinically relevant non-major bleeding and major adverse cardiac and cerebrovascular events (MACCE) were assessed up to 30 days post-procedure.

Results

Bleeding was less frequent with ≤1 week versus 1 month of TAT

SUBMITTER: Sammut MA 

PROVIDER: S-EPMC11262428 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature